Fig. 1 | Scientific Reports

Fig. 1

From: Management of COVID-19 associated coagulopathy in critically ill patients and the risk of acquired von willebrand syndrome

Fig. 1

Comparison of coagulation/fibrinolysis markers at each time point between the ECMO and non-ECMO groups.

Solid lines indicate the ECMO group, and dotted lines indicate the non-ECMO group. P-values indicate comparisons between groups for each period.

*P < 0.05, **P < 0.01 for comparisons between the linked groups at each point. The gray area indicates the reference range.

Point 1 (P-1): day 1 (at intensive care unit admission in both groups, and before starting vvECMO in the ECMO group), Point 2 (P-2): day 3 or 4 (ECMO group: third day after starting vvECMO, non-ECMO group: day 3), and Point 3 (P-3): day 6 to 7 (ECMO group: sixth day after starting vvECMO, non-ECMO group: day 6 or 7).

ECMO, extracorporeal membrane oxygenation; vv, venovenous; PLT, platelet; PT-INR, prothrombin time–international normalized ratio; aPTT, activated partial thromboplastin time; Fbg, fibrinogen; FDP, fibrin/fibrinogen degradation products; TAT, thrombin–antithrombin complex; PIC, plasmin α2–plasmin inhibitor complex; PAI-1, plasminogen activator inhibitor-1; AT, antithrombin; SF, soluble fibrin.

Back to article page